High purity component helps optimise and better control the cost of manufacturing
Dow Oxygenated Solvents, a business unit of The Dow Chemical Company, has introduced Valeric Acid Ultrapure, a high purity component that helps optimise and better control the cost of manufacturing angiotensin receptor blockers (ARBs) such as Valsartan, which are widely used to treat high blood pressure (hypertension) and heart failure.
The ARBs block the action of angiotensin II, a potent chemical that causes muscles surrounding blood vessels to contract and narrow, leading to elevated blood pressure or hypertension.
Pailloux said the high purity of (99.3% min.) of the product and its very low levels of butyric acid (0.02% max.) can be especially beneficial to producers of n-valeryl chloride because impurities such as n-butyric acid derivatives, which can impede the performance of blood pressure medications, are difficult to isolate during medicine production.
According to Pailloux, DOW Valeric Acid Ultrapure helps eliminate impurities to protect medicine potency while maximising process yields and reducing the need for additional impurity testing.
‘This enhanced product reflects our ongoing commitment to delivering high quality solvent products that help maximise the process efficiency of Dow customers in the pharmaceutical manufacturing industry,’ said Xavier Pailloux, marketing manager, Oxygenated Solvents.